Diabetes is bleeding Indians dry

NEW DELHI: The mounting prevalence of diabetes with complications like obesity, blood pressure and cholesterol among Indians is leading to spiralling cost of treatment and a massive burden on out-of pocket expenditure.

The total healthcare expenditure on diabetes in India was estimated at $31 billion in 2017 with 86% of rural and 82% of urban populations in India having to bear the costs of disease management through out-of pocket expenses, a new study published in Lancet shows.

According to the study, the expenditure of an average Indian patient with type 2 diabetes was estimated to be $95 per year. The costs of care include direct, indirect, and intangible costs.

Diabetes is bleeding Indians dry
Though use of low cost drugs and insulin have helped keep the expenditure on diabetes management under check, the enormous cost is driven by increasing prevalence of diabetes, mainly with complications. Researchers also observed that gradually use of (and thus expenditure on) newer oral drugs and insulins are increasing in India.

Diabetes prevalence has increased by 64% across India over the quarter-century. According to International Diabetes Federation, India’s diabetes population totalled 74 million in 2017 and it is estimated to reach 134.3 million people by 2045.

“When complications occur, these costs increase exponentially, particularly when insulin is initiated or admission to hospital or surgery are required…” says Dr Anoop Misra, chairman, Fortis C-Doc. He is one of the authors of the study. Other researchers include Nikhil Tandon from AIIMS and Andrew P Hills from University of Tasmania. The study linked higher spend on the disease management with higher income. In India, infections contribute to 41% of deaths among patients with diabetes.

ETPrime

Polio virus to India: The news of my death has been grossly exaggerated. Hello again!
NewsletterA A

inShare

Subscribe ETHealthworld Newsletter
150000+ Industry Leaders already read it everyday

Your Email

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug